After several decades of development, AAV vector-mediated gene therapy is now an option for treating retinal dystrophy, spinal muscular atrophy, Duchenne muscular dystrophy, aromatic L-amino acid decarboxylase deficiency, and hemophilia.31 This evidence concerns the gene DDC and proximal spinal muscular atrophy.